SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3457Sounded like on the call, they are designing a new trial that will satisfy fda fCuttingEdge Bio-2/16/2022
3456clinicaltrials.gov They already had a trial going to replace one of the mAbs. BioBait-2/16/2022
3455Only a P2 was required for EUA. Not sure if REGN has their next gen in clinic yFelix B-2/15/2022
3454Lilly's bebtelovimab receives Emergency Use Authorization for the treatment BioBait-2/15/2022
3453What they are planning to do is to show a non-inferiority result between the 12wCuttingEdge Bio-2/14/2022
3452It was "sarcastic" note, but there is small concern... 12 w interval wMiljenko Zuanic-2/14/2022
3451No, because the phase 3 has a different trial design than CANDELA. The phase 3 CuttingEdge Bio-2/14/2022
3450Yes, I am drawing attention to that slide as my answer to the question. Not arguCuttingEdge Bio-2/14/2022
3449<4 weeks following the shot (of either dose) would be the same, as it is at aMiljenko Zuanic-2/13/2022
3448investor.regeneron.com Slide 8 What is a point of argue???? David asked "wMiljenko Zuanic-2/13/2022
3447<The VEGF arm of the bispecific is at a higher molar dose than Lucentis is atMiljenko Zuanic12/13/2022
3446Week 44 would have been the next dose if the study continues beyond this time peCuttingEdge Bio-2/13/2022
3445Not really. The VEGF arm of the bispecific is at a higher molar dose than LucentCuttingEdge Bio-2/13/2022
3444investor.regeneron.com Initial data (if hold in p3) demonstrate that Eylea 8 mg Miljenko Zuanic12/13/2022
3443Other explanation is: 16 +24 (2 extended dose, 12 weeks apart) + 4 weeks for outMiljenko Zuanic-2/13/2022
3442Would not characterize it that way? ang2 seams does bring benefits to Lucentis aMiljenko Zuanic-2/13/2022
3441Do not know. CANDELA study does not describe P2 trial extension, it should be 16Miljenko Zuanic-2/13/2022
3440All a big ruse. "Innovation!" They increased molar dose of VEGF and CuttingEdge Bio-2/12/2022
3439Why did REGN report data at 44 weeks (which is an unusual cutoff time)?DewDiligence_on_SI-2/12/2022
3438So basically Roche is injecting ang2 in patients unnecessarily?BioBait-2/12/2022
34378 mg Eylea seam in line with Roche bispecific: investor.regeneron.com The key fMiljenko Zuanic-2/11/2022
3436Podium Session 13: Hearing Loss: the Road From Genetics to TherapiesBioBait-2/5/2022
34352021 guesstimate Dupi 4b +50% +2b Eylea 8b +10% .8b Cov2 US +3b ROW +3b (possiBioBait-2/4/2022
3434Regn-COV2 reported 7.5b in revenue. Even if there’s no gen2 it’s a big win. MBioBait12/4/2022
3433REGN is working hard (means, at least spending $$$) on new therapeutic modalitieMiljenko Zuanic-2/4/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News